# US 2026/0216186 A1 · Compositions and methods of use for modified release minoxidil

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216186 A1
- Document ID: US20260216186A1
- Status: Published application
- Kind: A1
- Application number: 19/572,667
- Filed: 2026-03-19
- Published: 2026-07-30
- Earliest claimed: 2022-10-25
- Assignees: Veradermics Incorporated
- Applicants: Veradermics, Incorporated
- Inventors: Reid WALDMAN
- Web page: https://patentgrep.com/patent/US20260216186A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61P 17/14: for baldness or alopecia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating hair loss, comprising orally administering a daily dose of about 15-18 mg of minoxidil, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, to a patient in need thereof, wherein the daily dose of about 15-18 mg of the minoxidil or the molar equivalent amount of the pharmaceutically acceptable salt thereof is administered in a dosage form that provides modified release of minoxidil or the pharmaceutically acceptable salt thereof, wherein the patient experiences reduced tachyarrhythmia while the dosage form is being administered to the patient as compared to tachyarrhythmia that the patient would experience if a dosage form providing immediate release of a daily dose of about 15-18 mg of minoxidil were administered to the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dosage form is administered once a day.

### Claim 3 (depends on 1)

The method of claim 1, wherein the dosage form is administered twice a day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dosage form comprises about 20% to about 95% of a release modifier, by weight of the dosage form.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dosage form further comprises about 0.01% to about 2% of a glidant, by weight of the dosage form.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dosage form further comprises about 0.1% to about 1% of a lubricant, by weight of the dosage form.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dosage form further comprises about 20% to about 65% of a filler, by weight of the dosage form.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dosage form further comprises about 1% to about 10% of a coating, by weight of the dosage form.

### Claim 9 (depends on 1)

The method of claim 1, wherein the dosage form further comprises about 1% to about 10% of a hydroxypropyl methylcellulose coating of the dosage form.

### Claim 10 (depends on 1)

The method of claim 1, wherein the dosage form further comprises about 1% to about 10% of a polyvinyl alcohol coating, by weight of the dosage form.

### Claim 11 (depends on 1)

The method of claim 1, wherein the dosage form further comprises a 5-alpha reductase inhibitor.

### Claim 12 (depends on 1)

The method of claim 1, wherein no peripheral edema is observed in the patient.

### Claim 13 (depends on 1)

The method of claim 1, wherein no tachycardia is observed in the patient.

### Claim 14 (depends on 1)

The method of claim 1, wherein no hypotension is observed in the patient.

### Claim 15 (depends on 1)

The method of claim 1, wherein no lightheadedness is observed in the patient.

### Claim 16 (depends on 1)

The method of claim 1, wherein no hirsutism is observed in the patient.

### Claim 17 (depends on 1)

The method of claim 1, wherein the patient experiences less peripheral edema than the patient would have experienced if the same dose of immediate release minoxidil, or the pharmaceutically acceptable salt thereof, were administered to the patient.

### Claim 18 (depends on 1)

The method of claim 1, wherein the patient experiences less tachycardia than the patient would have experienced if the same dose of immediate release minoxidil, or the pharmaceutically acceptable salt thereof, were administered to the patient.

### Claim 19 (depends on 1)

The method of claim 1, wherein the patient experiences less hypotension than the patient would have experienced if the same dose of immediate release minoxidil, or the pharmaceutically acceptable salt thereof, were administered to the patient.

### Claim 20 (depends on 1)

The method of claim 1, wherein the patient experiences less lightheadedness than the patient would have experienced if the same dose of immediate release minoxidil, or the pharmaceutically acceptable salt thereof, were administered to the patient.
